A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.

In fluctuating Parkinson's disease (PD) patients, treatment of PD using the catechol-O-methyl transferase inhibitor entacapone with carbidopa/levodopa improves quality of life and activities of ...

GOTHENBURG, SWEDEN / ACCESSWIRE / November 13, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, November ...

This new, non-surgical regimen provides continuous delivery of levodopa morning, day, and night,” Robert A. Hauser, MD, MBA, director of the Parkinson's and Movement Disorder Center at the ...

Foscarbidopa and foslevodopa are pro-drugs for carbidopa and levodopa, which are standard-of-care Parkinson's treatments. The new treatment, formerly know as ABBV-951, is the first subcutaneous 24 ...

for adults living with advanced Parkinson's disease (PD). Vyalev is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in ...

The therapy is delivered as a 24-hour continuous infusion to treat motor fluctuations in adults with advanced Parkinson’s. AbbVie already markets a carbidopa and levodopa combination with Duopa.

The researchers note that, "despite the similarities, patients with these diseases have a different prognosis and do not ...

Medication can be helpful in improving the main symptoms of Parkinson's disease, such as shaking and movement problems. There ...

The first levodopa-based treatment for motor fluctuations in people with advanced Parkinson's disease, VYALEVa subcutaneous 24-hour continuous infusion of foscarbidopa and foslevodopais now ...

Levodopa-induced dyskinesia (LID) is a common complication after dopamine-replacement therapy in Parkinson's disease. The neural mechanisms underlying LID are far from clear, although significant ...